Chemed (NYSE:CHE) updated its FY 2018 earnings guidance on Monday. The company provided earnings per share guidance of $11.80-11.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.47.
A number of brokerages recently weighed in on CHE. ValuEngine cut shares of Chemed from a strong-buy rating to a buy rating in a research report on Thursday, August 2nd. Zacks Investment Research raised shares of Chemed from a hold rating to a buy rating and set a $350.00 price target for the company in a research report on Tuesday, July 31st. Bank of America began coverage on shares of Chemed in a research report on Friday, October 12th. They set a buy rating and a $390.00 price target for the company. Finally, Royal Bank of Canada upped their price target on shares of Chemed to $321.00 and gave the stock a market perform rating in a research report on Monday, July 30th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Chemed presently has an average rating of Buy and a consensus target price of $334.00.
Chemed stock traded down $9.06 during trading on Monday, reaching $278.75. 140,400 shares of the company’s stock were exchanged, compared to its average volume of 138,280. The company has a current ratio of 1.04, a quick ratio of 1.01 and a debt-to-equity ratio of 0.19. Chemed has a 52-week low of $219.35 and a 52-week high of $335.99. The stock has a market cap of $4.63 billion, a price-to-earnings ratio of 51.97, a price-to-earnings-growth ratio of 2.58 and a beta of 1.17.
Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
See Also: Diversification
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.